Global Formulation Development Outsourcing Market Research Report—Forecast till 2027

Global Formulation Development Outsourcing Market Research Report—Forecast till 2027

Market Dynamics
Global Formulation Development Outsourcing Market is estimated to exhibit a significant CAGR of 8.19% during the review period of 2020 to 2027, to surpass USD 13,530.01 Million by 2027. The formulation development is the area of product development that can determine patentability, lifecycle, and, ultimately, the achievement of a pharmaceutical product. Many companies integrate formulation development functions and personnel into their product development cycle in many ways. The global market growth is attributed to the increasing focus of biopharmaceutical companies establishing a partnership with academia, Contract Research Organizations (CROs), and biotechnology start-up companies to develop formulation against diseases. Additionally, the increasing demand for outsourcing of services from pharmaceutical companies and the presence of market players involved in new services and strategic collaborations are further propelling the growth of the formulation development outsourcing market during the review period.
The global formulation development outsourcings market is set to witness substantial market growth during the review owing to the patent protection expiration of major drugs. Moreover, the rising number of pharmaceutical and biopharmaceutical companies outsourcing their services in the industry have opened new opportunities for the formulation development outsourcing manufacturers. However, structural changes in the pharmaceutical industry and insufficient funding to carry out the drug development process through formulation development outsourcing in developing are hindering market growth during the review period.

Market Segmentation
The global formulation development outsourcing market has been classified into services, dosage form, application, and end-user.
Based on services, the global market has been classified into preformulation services and formulation optimization. Preformulation services are further divided into formulation discovery, pre-clinical services, and analytical services. Formulation optimization is further segmented into Phase I, Phase II, Phase III, and Phase IV.
In terms of the global formulation development outsourcing market has been categorized into oncology, genetic disorders, neurology, infectious diseases, respiratory, cardiovascular, and others.
Based on the end-user segment the global formulation development outsourcing market has been divided into pharmaceutical & biopharmaceutical companies, government, and academic institutes.
Regional Analysis
Geographically, the global formulation development outsourcing market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to contribute the largest share of the global market owing to the spearheaded market in 2019. The regional market is driven by the presence of a well-established healthcare system and the increasing prevalence of chronic diseases & the need for drug development.
Europe is expected to register the second largest market during the review period owing to the presence of favorable government initiatives, and large target population base, an increasing prevalence of chronic and lifestyle-associated conditions, and rising adoption of formulation development outsourcing by pharmaceutical and biopharma companies.
The global formulation market in Asia-Pacific is anticipated to register the fastest market growth potential over the review period owing to growing per capita health expenditure, the emerging healthcare sector in China, India, and Australia, growing demand for the drug development process, and the increasing number of pharmaceutical companies involved in drug development.
Major Players
The major players in the global formulation development outsourcing market include Laboratory Corporation of America (US), Charles River Laboratories (US), Catalent, Inc. (US), and Intertek (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS 16

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 17

2.2 RESEARCH OBJECTIVE 17

2.3 LIST OF ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY
3.1 OVERVIEW 19

3.2 DATA MINING 19

3.3 SECONDARY RESEARCH 20

3.4 PRIMARY RESEARCH 21

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 22

3.5 FORECASTING TECHNIQUES 23

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 24

3.6.1 BOTTOM-UP APPROACH 24

3.6.2 TOP-DOWN APPROACH 25

3.7 DATA TRIANGULATION 25

3.8 VALIDATION 25

4 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES
4.1 INTRODUCTION 26

4.2 PREFORMULATION SERVICES 27

4.2.1 FORMULATION DISCOVERY 28

4.2.2 PRECLINICAL SERVICES 28

4.2.3 ANALYTICAL SERVICES 29

4.3 FORMULATION OPTIMIZATION 29

4.3.1 PHASE I 30

4.3.2 PHASE II 30

4.3.3 PHASE III 31

4.3.4 PHASE IV 31

5 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM
5.1 INTRODUCTION 32

5.2 INJECTABLE 34

5.3 ORAL 34

5.4 TOPICAL 35

5.5 INHALED 35

5.6 OTHERS 36

6 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION
6.1 INTRODUCTION 37

6.2 ONCOLOGY 39

6.3 GENETIC DISORDERS 40

6.4 NEUROLOGY 40

6.5 INFECTIOUS DISEASES 41

6.6 RESPIRATORY 41

6.7 CARDIOVASCULAR 42

6.8 OTHERS 42

7 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER
7.1 INTRODUCTION 43

7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 44

7.3 GOVERNMENT & ACADEMIC INSTITUTES 44

8 GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION
8.1 INTRODUCTION 45

8.2 AMERICAS 46

8.2.1 NORTH AMERICA 48

8.2.1.1 US 51

8.2.1.2 CANADA 53

8.2.2 LATIN AMERICA 55

8.3 EUROPE 58

8.3.1 WESTERN EUROPE 61

8.3.1.1 GERMANY 63

8.3.1.2 FRANCE 65

8.3.1.3 UK 67

8.3.1.4 ITALY 69

8.3.1.5 SPAIN 71

8.3.1.6 REST OF WESTERN EUROPE 73

8.3.2 EASTERN EUROPE 75

8.4 ASIA-PACIFIC 78

8.4.1 JAPAN 80

8.4.2 CHINA 82

8.4.3 INDIA 84

8.4.4 AUSTRALIA 86

8.4.5 SOUTH KOREA 88

8.4.6 REST OF ASIA-PACIFIC 90

8.5 MIDDLE EAST & AFRICA 93

8.5.1 MIDDLE EAST 95

8.5.2 AFRICA 97

9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW 100

9.2 MARKET SHARE ANALYSIS 100

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 101

9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 102

9.5 KEY DEVELOPMENT ANALYSIS 102

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 103

9.6.1 ACQUISITION ACTIVITIES 103

9.6.2 EXPANSION 104

9.6.3 FINANCIAL MATRIX 104

9.6.4 R&D EXPENDITURE 104

10 COMPANY ANALYSIS
10.1 CHARLES RIVER LABORATORIES 105

10.2 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 106

10.3 CATALENT, INC. 108

10.4 LABORATORY CORPORATION OF AMERICA 109

10.5 SYNGENE INTERNATIONAL LTD. 110

10.6 IRISYS, LLC 111

10.7 INTERTEK 112

10.8 PIRAMAL ENTERPRISES LTD. 113

10.9 QUOTIENT SCIENCES 114

10.10 PATHEON (THERMO FISHER SCIENTIFIC) 115

10.11 EMERGENT BIOSOLUTIONS INC. 116

10.12 LONZA 117

10.13 PCI 118

10.14 DR. REDDY’S LABORATORIES LTD. 118

11 COMPANY PROFILES
11.1 AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 119

11.1.1 COMPANY OVERVIEW 119

11.1.2 FINANCIAL OVERVIEW 119

11.1.3 PRODUCTS/SERVICES OFFERED 119

11.1.4 KEY DEVELOPMENTS 121

11.1.5 SWOT ANALYSIS 122

11.1.6 KEY STRATEGIES 122

11.2 IRISYS, INC. 123

11.2.1 COMPANY OVERVIEW 123

11.2.2 FINANCIAL OVERVIEW 123

11.2.3 PRODUCTS/SERVICES OFFERED 123

11.2.4 KEY DEVELOPMENTS 124

11.2.5 SWOT ANALYSIS 125

11.2.6 KEY STRATEGIES 125

11.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 126

11.3.1 COMPANY OVERVIEW 126

11.3.2 FINANCIAL OVERVIEW 126

11.3.3 PRODUCTS OFFERED 127

11.3.4 KEY DEVELOPMENTS 128

11.3.5 SWOT ANALYSIS 128

11.3.6 KEY STRATEGIES 128

11.4 INTERTEK GROUP PLC 129

11.4.1 COMPANY OVERVIEW 129

11.4.2 FINANCIAL OVERVIEW 129

11.4.3 PRODUCTS/SERVICES OFFERED 130

11.4.4 KEY DEVELOPMENTS 131

11.4.5 SWOT ANALYSIS 131

11.4.6 KEY STRATEGIES 131

11.5 CATALENT, INC. 132

11.5.1 COMPANY OVERVIEW 132

11.5.2 FINANCIAL OVERVIEW 132

11.5.1 PRODUCTS/SERVICES OFFERED 133

11.5.2 KEY DEVELOPMENTS 134

11.5.3 SWOT ANALYSIS 134

11.5.4 KEY STRATEGIES 135

11.6 SYGENE INTERNATIONAL LIMITED 136

11.6.1 COMPANY OVERVIEW 136

11.6.2 FINANCIAL OVERVIEW 136

11.6.3 PRODUCTS/SERVICES OFFERED 137

11.6.4 KEY DEVELOPMENTS 138

11.6.5 SWOT ANALYSIS 139

11.6.6 KEY STRATEGIES 139

11.7 LABORATORY CORPORATION OF AMERICA HOLDINGS 140

11.7.1 COMPANY OVERVIEW 140

11.7.2 FINANCIAL OVERVIEW 140

11.7.3 PRODUCTS/SERVICES OFFERED 141

11.7.4 KEY DEVELOPMENTS 141

11.7.5 SWOT ANALYSIS 142

11.7.6 KEY STRATEGIES 142

11.8 PATHEON (THERMO FISHER SCIENTIFIC) 143

11.8.1 COMPANY OVERVIEW 143

11.8.2 FINANCIAL OVERVIEW 143

11.8.3 PRODUCTS/SERVICES OFFERED 144

11.8.4 KEY DEVELOPMENTS 145

11.8.5 SWOT ANALYSIS 145

11.8.6 KEY STRATEGIES 146

11.9 QUOTIENT SCIENCES 147

11.9.1 COMPANY OVERVIEW 147

11.9.2 FINANCIAL OVERVIEW 147

11.9.3 PRODUCTS/SERVICES OFFERED 147

11.9.4 KEY DEVELOPMENTS 148

11.9.5 SWOT ANALYSIS 148

11.9.6 KEY STRATEGIES 148

11.10 EMERGENT BISOLUTIONS INC. 149

11.10.1 COMPANY OVERVIEW 149

11.10.2 FINANCIAL OVERVIEW 149

11.10.3 PRODUCTS/SERVICES OFFERED 149

11.10.4 KEY DEVELOPMENTS 150

11.10.5 SWOT ANALYSIS 150

11.10.6 KEY STRATEGIES 150

12 APPENDIX
12.1 REFERENCES 151

12.2 RELATED REPORTS 152